In 2022, the transarterial chemoembolization (TACE) market was estimated to be worth USD 10.9 billion. The industry for transarterial chemoembolization (TACE) is expected to increase at a compound annual growth rate (CAGR) of 4.90% between 2023 and 2032, from USD 11.4 billion in 2023 to USD 16.8 billion.
The Transarterial Chemoembolization (TACE) Procedure market is expanding as a primary treatment option for liver cancer. TACE procedure involves delivering chemotherapy directly to the tumor site, followed by embolization to block blood flow. With its minimally invasive nature and efficacy, TACE is increasingly favored, driving growth in the market for this procedure.
The Transarterial Chemoembolization (TACE) Market is experiencing substantial growth due to its efficacy in treating liver cancer, particularly hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that combines chemotherapy and embolization to target and destroy cancerous tumors in the liver while minimizing systemic side effects.
The market offers a variety of TACE products and devices, including catheters, microcatheters, embolic agents, and chemotherapeutic drugs, tailored to specific patient needs and clinical preferences. Moreover, the availability of drug-eluting beads and radioembolization techniques further expands the treatment options for patients with liver cancer.
Furthermore, collaborations between healthcare providers, research institutions, and industry players drive innovation and clinical research in the field of TACE, leading to the development of novel treatment strategies and devices.
Market Segmentation:
By Application: The market is divided into three applications: chemotherapeutic agents, radiotherapeutic agents, and drug-eluting particles.
By end-users: The market is divided into Hospitals & Clinics and Cancer Research Centers based on propulsion type.
Regional Classification:
The worldwide Transarterial Chemoembolization (TACE) Market is segmented into America, Europe, Asia Pacific, the Middle East, and Africa, according to the studies. Because of greater awareness of HCC and early identification, the market for transarterial chemoembolization (TACE) is expanding rapidly in the United States. As a result, the American Association of Liver Diseases recommends that persons at risk for HCC have hepatic imaging every 6 months to monitor their health. Europe's healthcare systems are among the best in the world. As a result of rising healthcare expenses, the transarterial chemoembolization (TACE) industry is seeing increased demand. THE EUROPEAN COMMISSION estimates that overall EU government spending accounted for 45.8 percent of GDP in 2017, with health care spending accounting for 7.0 percent. Asia-Pacific is home to the fastest-growing TACE global market as the world's most populous region and a location where hepatocellular carcinoma is becoming more widespread.
Key Players –
Transarterial Chemoembolization (TACE) companies comprise Advaxis Inc., Baxter, Bellicum Pharmaceuticals, Boston Scientific Corporation, Cook, Hikma Pharmaceuticals PLC, Isofol Medical AB, Nippon Kayaku Co., Novartis, Pfizer, Sirtex SIR-Spheres Pty Ltd., and Spectrum Pharmaceuticals.
For more information visit at MarketResearchFuture
